Johnson & Johnson Announces Conditional $5.5B Ovarian Talc Settlement

What Happened

• On July 27, 2026 (filed via Form 8-K on July 28, 2026), Johnson & Johnson announced a reached agreement with plaintiff firms leading the federal MDL and related state court proceedings to comprehensively resolve ovarian talc litigation. The agreement provides for per‑claim payments and reflects a company commitment of $5.5 billion, with a first payment of no more than $3 billion to be made in 2027 and no additional payments required before 2028. The deal is conditioned on the express participation of at least 95% of the remaining claims.

Key Details

• $5.5 billion: Johnson & Johnson’s total commitment under the agreement.
• Up to $3.0 billion: maximum initial payment scheduled for 2027.
• Timing condition: no additional payments are due before 2028.
• Participation threshold: agreement conditioned on at least 95% of remaining claims opting in; payments are structured on a per‑claim basis.
• Disclosure type: announced under Regulation FD and attached as a July 27, 2026 press release (Exhibit 99.1) to the Form 8‑K.

Why It Matters

• This announcement addresses a major legal exposure for J&J by providing a framework to resolve the ovarian talc cases, which could reduce future litigation uncertainty if the participation threshold is met.
• Financially, the commitment establishes a material potential cash outflow (up to $5.5B total, with up to $3B in 2027) that investors should monitor in company disclosures and future financial statements for effects on cash flow, reserves and guidance.
• The agreement is conditional (95% participation required); until that threshold is met and payments are made, the timing and total financial impact remain subject to change.